SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Aviron
AVIR 3.070-12.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (72)7/31/1997 8:10:00 PM
From: Pseudo Biologist   of 645
 
Brad,

Thanks for the clarification on pricing and market potential.

I am no flu expert by any means, but people I talked to who are more atuned to the world of viruses are impressed by the reported data.

On the FDA issue, an interesting recent situation with some superficial resemblance is that of Neurex's Corlopam. The compound was discovered, developed thru several clinical stages, and dropped before being outlicensed to Neurex. The latter thus had little control over a lot (maybe all?) of the clinical data. I am not saying the situations are equivalent, but what happened with Neurex, Corlopam and the FDA may give some insight on the kinds of issues Aviron may be facing in a year or two as it regards your concerns.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News